Nivalis Therapeutics ALPN 深 沪
已收盘 05-20 16:00:00 美东时间
64.97
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 64.97
- 总市值 42.59亿
- 52周最高 65.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.33
- 委 比 0.00%
- 总股本 6554.61万
- 历史最高 65.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.05
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多药物受理最新动态：Alpine Immune Sciences, Inc.ALPN-303 注射液补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年10月26日，Alpine Immune Sciences, Inc.的ALPN-303 注射液申请已获受理...
10-26 11:15
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.13% on Oct 13: What Investors Need To Know
• Vertex faced downward price pressure from biotech sector weakness and technical selling. • Core fundamentals remain supported by cystic fibrosis leadership and pipeline diversification. • Technical indicators show a MACD sell signal and Williams %R oversold condition.
10-13 16:15
Arcutis Expands Board of Directors with Appointment of Chris Peetz
Arcutis Biotherapeutics appoints Chris Peetz to its Board of Directors. Peetz, a biopharmaceutical executive with extensive experience, will help the company expand its ZORYVE franchise and pipeline. ZORYVE, a topical PDE4 inhibitor, is the leading branded therapy for inflammatory skin diseases. Peetz's leadership is expected to drive Arcutis' growth and innovation in immuno-dermatology.
07-16 13:00
Wedbush：重申Alpine Immune Sciences(ALPN.US)评级，由中性调整至中性评级, 目标价65.00美元。
Wedbush：重申Alpine Immune Sciences(ALPN.US)评级，由中性调整至中性评级, 目标价65.00美元。
2024-05-16 20:40
Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last year. The company
2024-05-10 04:25
Alpine Immune Sciences Communicates Key Updates Regularly
The latest announcement is out from Alpine Immune Sciences Inc (ALPN). Alpine I...
2024-05-10 04:24
